Publication: 3111

Publication: 3111

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial.

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Oncologist vol 24 (11) 1497-1501

Year:: 2019
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: Received

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 9

Parents:: 2909 2998
Children:: None

Program:: OGC
Primary Committee:: GU
Sec. Committees:

Pharmas:: Exelixis, Inc
Grants:: U10CA180821, U10CA180882, U10CA180791, U10CA180833, U10CA180850, U10CA180857, U10CA180867, P30 CA008748

Corr. Author:
Authors:: Daniel J George Colin Hessel Susan Halabi M Dror Michaelson Olwen Hahn Meghara Walsh Joel Picus Eric J Small Shaker Dakhil Darren R Feldman Milan Mangeshkar Christian Scheffold Michael J Morris Toni K Choueiri

Networks:: CA824, KS055, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NC010, LAPS-NY016

Study: Alliance-A031203
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords:: Aged, Anilides, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Carcinoma, Renal Cell, Female, Follow-Up Studies, Humans, Kidney Neoplasms, Male, Prognosis, Pyridines, Retrospective Studies, Sunitinib, Survival Rate